Clinical trial
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin…
NCT02168686 · Adverum Biotechnologies, Inc., Industry · Completed
Key facts
| NCT number | NCT02168686 |
|---|---|
| Title | Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency |
| Official title | Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency |
| Acronym | ADVANCE |
| Lead sponsor | Adverum Biotechnologies, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Alpha 1-Antitrypsin Deficiency |
| Intervention type | Genetic |
| Interventions | ADVM-043 |
| Enrollment | 6 |
| Start date | Nov 28, 2017 |
| Primary completion | Aug 29, 2019 |
| Completion | Aug 29, 2019 |
| First posted | Jun 20, 2014 |
| Last update posted | Oct 5, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: